 FARMINGTON HILLS, Mich., Oct. 01, 2021 GLOBE NEWSWIRE -- Ocuphire Pharma, Inc. Nasdaq: OCUP, a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced that its clinical-stage, novel oral Ref-1 inhibitor, APX3330, for the treatment of diabetic retinal disease will be featured at the Ophthalmology Innovation Summit OIS RetinaASRS Innovation Company Showcase on October 7 in San Antonio, TX. The APX3330 abstract was accepted for podium presentation and discussion at the 39th Annual Meeting of the American Society of Retina Specialists ASRS, to take place October 8 12 in San Antonio, TX. 